Emerging antiretroviral drug interactions

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 2, 2011, Pages 235-239

  Pham, Paul A ^a   Flexner, Charles ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulants; Antituberculosis; Chemotherapy; HIV; Pulmonary hypertension

Indexed keywords

AMBRISENTAN; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ARTEMISININ; BENFLUMETOL; BOSENTAN; CLOPIDOGREL; CYCLOPHOSPHAMIDE; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DOXORUBICIN; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MEFLOQUINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMEPRAZOLE; PREDNISONE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RITONAVIR; SILDENAFIL; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VINCRISTINE; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; COMORBIDITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG INHIBITION; DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LOW DRUG DOSE; MALARIA; NONHODGKIN LYMPHOMA; PULMONARY HYPERTENSION; THROMBOSIS; TUBERCULOSIS;

ANTI-RETROVIRAL AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS;

EID: 78651459148     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq448     Document Type: Article

References (35)

1. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. December 1, 2009. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (18 July 2010, date last accessed).
2. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-26.
3. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
4. Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 2010; 50 Suppl 3: S223-30.
5. Centers for Disease Control and Prevention. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm (25 March 2010, date last accessed).
6. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49: 1305-11.
7. Brainard DM, Petry AS, Fang L, et al. Lack of a clinically important effect of rifabutin on raltegravir pharmacokinetics. In: Abstracts of the Forty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract A1-1296. American Society for Microbiology, Washington, DC, USA.
8. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis 2008; 198: 948-61.
9. van Vugt M, Ezzet F, Nosten F, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 1999; 61: 964-7.
10. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-9.
11. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
12. Liedtke MD, Rathbun RC. Warfarin-antiretroviral interactions. Ann Pharmacother 2009; 43: 322-8.
13. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-31.
14. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS 1999; 13: 1788-9.
15. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998; 32: 1299-302.
16. Darunavir [package insert]. East Bridgewater, NJ: Tibotec Therapeutics, April 2010.
17. Liu P, Foste G, LaBadie RR, et al. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008; 48: 73-84.
18. Schöller-Gyüre M, Kakuda TN, Stevens T, et al. Effect of etravirine on cytochrome P450 isozymes assessed by the Cooperstown 5+1 cocktail. In: Abstracts of the Forty-Eighth Interscience Conference on Antimicrobial Agents, Washington, DC, USA, 2008. Abstract A-955. American Society for Microbiology, Washington, DC, USA.
19. Gilard M, Arnaud B, Cornily J, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008; 51: 256-60.
20. Ho MP, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
21. Clopidogrel [package insert]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, May 2009.
22. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-54.
23. Navarro JT, Ribera JM, Oriol A, et al. Influenceofhighlyactive anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112: 909-15.
24. Bohlius J, Schmidlin K, Costagliola D, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009; 23: 2029-37.
25. Hentrich M, Maretta L, Chow KU, et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol 2006; 17: 914-9.
26. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91: 155-63.
27. Ratner L, LeeJ, Tang S, et al. Chemotherapy forhuman immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J ClinOncol 2001; 19: 2171-8.
28. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial. Cancer 2006; 106: 1560-8.
29. Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest 1991; 100: 1268-71.
30. Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010; 24: 67-75.
31. Degano B, Yaïci A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009; 33: 92-8.
32. Richards DB, Walker GA, Mandagere A, et al. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol 2009; 49: 719-24.
33. Muirhead GJ, Wulff MB, Fielding A, et al. Pharmocokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50: 99-107.
34. Rosenkranz B, Fischer C, Frolich JC. Prostacyclin metabolites in human plasma. Clin Pharmacol Ther 1981; 29: 420-4.
35. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002; 95: 147-54.